Sale of all shares representing 85% of the capital of Extab Corporation

Pursuant to art.100k, par.1 of POSA we hereby notify, that the Board of Directors of Sopharma AD authorized the Executive Director to begin negotiations for the sale of all shares representing 85% of the capital of the subsidiary Extab Corporation, owned by Sopharma AD. The negotiations will be conducted as part of the strategy for development of the original products of Sopharma AD on new markets, on which the Company does not possess the necessary resources for such actions in the near future.